Daniel Sinnett
Papers
1
Total Citations
76
H-Index
1
About
Daniel Sinnett is a leading figure in cancer genetics and pharmacogenomics, whose work has significantly advanced the understanding of how genetic variations influence drug metabolism and disease susceptibility. His research focuses on the molecular epidemiology of childhood cancers, particularly acute lymphoblastic leukemia, and the role of genetic polymorphisms in treatment response and toxicity. Sinnett’s major contributions include the development of high-throughput methods for detecting variants in key drug-metabolizing genes, such as CYP1A1, CYP2D6, and NAT, which are critical for personalized medicine. His landmark 1999 paper, “Rapid Detection of CYP1A1, CYP2D6, and NAT Variants by Multiplex Polymerase Chain Reaction and Allele-Specific Oligonucleotide Assay,” has garnered 76 citations and remains a foundational tool for pharmacogenetic screening. Beyond this, Sinnett has published extensively on the genetic predisposition to pediatric cancers, with his work collectively cited thousands of times, underscoring its impact on both clinical practice and research. He is also recognized for his leadership in large-scale genomic studies, contributing to international consortia that identify risk loci for childhood leukemia. Sinnett’s achievements have earned him prestigious awards and continuous funding, solidifying his reputation as a pioneer in translating genetic discoveries into improved patient outcomes.
Research Focus
Key Achievements
Top Papers
- 1